GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (NAS:BIOR) » Definitions » Price-to-Owner-Earnings

Biora Therapeutics (Biora Therapeutics) Price-to-Owner-Earnings : (As of May. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-30), Biora Therapeutics's share price is $0.5989. Biora Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Biora Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


BIOR's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.475
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-30), Biora Therapeutics's share price is $0.5989. Biora Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.12. Therefore, Biora Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-30), Biora Therapeutics's share price is $0.5989. Biora Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-8.16. Therefore, Biora Therapeutics's PE Ratio without NRI for today is At Loss.


Biora Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Biora Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics Price-to-Owner-Earnings Chart

Biora Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Biora Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biora Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Biora Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biora Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biora Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Biora Therapeutics's Price-to-Owner-Earnings falls into.



Biora Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Biora Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.5989/-3.57
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biora Therapeutics  (NAS:BIOR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Biora Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Biora Therapeutics (Biora Therapeutics) Business Description

Traded in Other Exchanges
Address
4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.
Executives
Athyrium Opportunities Iii Co-invest 1 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Surbhi Sarna director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Aditya P. Mohanty director, officer: Chief Executive Officer 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Ann Howe director C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Athyrium Capital Management, Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Fund (a) Lp 10 percent owner 605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158
Hutan Hashemi officer: Chief Compliance Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Damon Silvestry officer: Chief Operating Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Jeffrey D. Alter director 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Iii Acquisition Lp 10 percent owner 505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017
Harry Stylli director, officer: Chairman & CEO 3595 JOHN HOPKINS CT, SAN DIEGO CA 92121
Matthew T Cooper officer: Chief Scientific Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Advisers Llc 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Gp Llc 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Lp 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104